Copyright
©The Author(s) 2022.
World J Clin Oncol. Jul 24, 2022; 13(7): 630-640
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.630
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.630
Survival analysis according to CA 19-9 values | |||
Ref. | n | CA 19-9 in U/mL | Survival |
Overall median survival in mo | |||
Berger et al[30], 2004 | 7 | Undetectable | 32 |
21 | ≤ 37 | 35 | |
44 | 38-200 | 22 | |
57 | > 200 | 16 | |
Ferrone et al[33], 2006 | Mean survival time in yr | ||
29 | < 37 | 2.3 | |
82 | ≥ 37 | 1.6 | |
Waraya et al[28], 2009 | Disease-specific survival in mo | ||
23 | ≤ 37 | 30.6 | |
66 | > 37 | 12.7 | |
Hirakawa et al[29], 2011 | Median survival in mo | ||
41 | Normal | 39.0 | |
84 | Elevated | 16.9 | |
Hartwig et al[32], 2011 | Median survival in mo | ||
232 | < 37 | 28.0 | |
418 | 37-399 | 23.5 | |
239 | ≥ 400 | 14.5 | |
Turrini et al[40], 2009 | Median survival in mo | ||
50 | < 37 | 22 | |
53 | 400-900 (n = 27), > 900 (n = 26) | 15 | |
Katz et al[34], 2010 | Median survival in mo | ||
21 | < 37 | 52.8 | |
78 | > 37 | 21.2 | |
Kondo et al[35], 2010 | Preoperative 3-yr survival (%) | ||
32 | < 37 | 57% | |
77 | > 37 | 30% | |
Hata et al[36], 2012 | Preoperative median survival in mo | ||
51 | < 37 | 16.2 | |
218 | > 37 | 16.4 | |
Bergquist et al[37], 2016 | Median OS in mo | ||
3666 | < 37 | 19.1 | |
7140 | > 37 | 14 | |
Jia et al[38], 2019 | Median OS in mo | ||
13 | < 35 | 21 | |
107 | ≥ 35 | 11 | |
Mattiucci et al[25], 2019 | Median OS in mo | ||
39 | 0-5.0 | 25 | |
167 | 5.1-37.0 | 38 | |
139 | 37.1-100.0 | 32 | |
178 | 100.1-353.0 | 22 | |
177 | > 353.1 | 20 | |
Kondo et al[26], 2017 | Median survival in mo | ||
65 | < 37 | 52.0 | |
84 | ≥ 37 | 23.7 | |
88 | < 50 | 52.0 | |
61 | ≥ 150 | 20.9 | |
101 | < 300 | 46.7 | |
48 | ≥ 300 | 18.8 | |
Dong et al[27], 2014 | Median OS in mo | ||
18 | < 37 | 21.6 | |
102 | ≥ 37 | 14.2 | |
Kang et al[31], 2007 | Disease free survival in mo | ||
18 | < 50 | 22.20 | |
43 | ≥ 50 | 19.31 | |
Kwon et al[14], 2020 | Median survival in d | ||
408 | < 37 | 644 | |
779 | > 37 | 340 | |
Survival analysis according to Lewis antigen status | |||
Luo et al[39], 2017 | Median survival in mo | ||
682 | 137 CA 19-9 (-) | Stage I, II: 16.6 in Lewis (-), 17.6 in Lewis (+) | |
47 Lewis (-) | Stage III, IV: 6.0 in Lewis (-), 7.8 in Lewis (+) | ||
Luo et al[11], 2018 | Median survival in mo | ||
1482 | 19.8% CA 19-9 (-) | 8.0 in Lewis (-) | |
8.4% Lewis (-) | 10.0 in Lewis (+) | ||
Kwon et al[14], 2020 | Median survival | ||
1187 | 203 CA 19-9 (-) | 356 d in Lewis (-) | |
375 Lewis (-) | 477 d in Lewis (+) |
- Citation: Balaban DV, Marin FS, Manucu G, Zoican A, Ciochina M, Mina V, Patoni C, Vladut C, Bucurica S, Costache RS, Ionita-Radu F, Jinga M. Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer. World J Clin Oncol 2022; 13(7): 630-640
- URL: https://www.wjgnet.com/2218-4333/full/v13/i7/630.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i7.630